← SynDRA
VAMOROLONE
SynDRA canonical compound SYN0037118 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | DMD | NFKB1 | NR3C1 |
|---|
| Mechanism of action | glucocorticoid receptor agonist |
|---|
| Indication | duchenne muscular dystrophy (dmd) |
|---|
| Disease area | genetics |
|---|
All known targets
Mechanisms of action (all sources)
- NR3C1 AGONIST
- NR3C2 ANTAGONIST
- Mineralocorticoid receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP2C9
- CYP2D6
- CYP3A4
- KCNH2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
ATC classes
- H02A · CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
Cross-references
Synonyms
- AGAMREE
- Agamree
- Vamorolona
- 9,11-dehydro dexamethasone
- 9,11-dehydrodexamethasone acetate
- Vamorolone acetate
- Vbp-15 free alcohol
- VBP-15
- VBP15
- UNII-8XP29XMB43
- VBP 15
- 8XP29XMB43
- CHEMBL2348780
- A-Methyl-9,11-dehydro Prednisolone
- Vamorolone [USAN]
- VBP-15 free alcohol
- EINECS 236-177-8
- AC1MHYKY
- Vamorolone (USAN/INN)
- SCHEMBL143459
- GTPL9247
- ZINC33650317
- dexamethasone impurity e (ep impurity)
- vamorolona
- vamorolonum
- RefChem:901612
- DTXCID601356317
- Dexamethasone EP Impurity E
- Agamree (TN)
- VAMOROLONE [INN]
- VAMOROLONE [WHO-DD]
- orb1307625
- CHEBI:228304
- GLXC-20144
- BDBM50432396
- VBP15-002
- AKOS027430312
- FM25760
Look up VAMOROLONE in the interactive SynDRA portal →